{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:41:27Z","timestamp":1775742087072,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011104","name":"Universitat Aut\u00f2noma de Barcelona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011104","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.urolonc.2021.05.006","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:17:14Z","timestamp":1623802634000},"page":"9.e9-9.e17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of clinical and pathological subtypes of carcinoma in situ (CIS) of the bladder: Lessons learned from long-term follow-up of a series of CIS patients treated with BCG"],"prefix":"10.1016","volume":"40","author":[{"given":"Jos\u00e9 Daniel","family":"Subiela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d3scar Rodr\u00edguez","family":"Faba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Aumatell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Krajewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Calder\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rub\u00e9n","family":"Parada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferran","family":"Algaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Breda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Palou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.urolonc.2021.05.006_bib0001","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.eururo.2014.10.040","article-title":"Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review","volume":"67","author":"Casey","year":"2015","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2021.05.006_bib0002","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.euf.2019.03.012","article-title":"Situ of the urinary bladder: a systematic review of current knowledge regarding detection, treatment, and outcomes","volume":"6","author":"Subiela","year":"2020","journal-title":"Eur Urol Focus."},{"issue":"4","key":"10.1016\/j.urolonc.2021.05.006_bib0003","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.05.006_bib0004","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2021.05.006_bib0005","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European association of urology guidelines on non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2021.05.006_bib0006","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/j.1464-410X.2010.09898.x","article-title":"The risk profiles of three clinical types of carcinoma in situ of the bladder","volume":"108","author":"Meijer","year":"2011","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.urolonc.2021.05.006_bib0007","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/S0022-5347(05)64994-4","article-title":"Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance","volume":"167","author":"Griffiths","year":"2002","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.urolonc.2021.05.006_bib0008","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1007\/s00432-019-02956-6","article-title":"Prognosis of carcinoma in situ according to the presence of papillary bladder tumors after bacillus Calmette-Guerin immunotherapy","volume":"145","author":"Kim","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2021.05.006_bib0009","first-page":"201","article-title":"Carcinoma in situ of urinary bladder: incidence, treatment and clinical outcomes during ten-year follow-up","volume":"51","author":"Librenjak","year":"2012","journal-title":"Acta Clin Croat"},{"issue":"3","key":"10.1016\/j.urolonc.2021.05.006_bib0010","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.21037\/tau.2020.03.40","article-title":"Clinical outcomes and survival differences between primary, secondary and concomitants carcinoma in situ of urinary bladder treated with BCG immunotherapy","volume":"9","author":"Piszczek","year":"2020","journal-title":"Transl Androl Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.05.006_bib0011","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-5347(05)67975-X","article-title":"Multivariate analysis of the prognostic factors of primary superficial bladder cancer","volume":"163","author":"Millan-Rodriguez","year":"2000","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.urolonc.2021.05.006_bib0012","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.acuro.2012.03.011","article-title":"[A second transurethral resection could be not necessary in all high grade non-muscle-invasive bladder tumors]","volume":"36","author":"Gaya","year":"2012","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.urolonc.2021.05.006_bib0013","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.urolonc.2021.05.006_bib0014","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/00365590410028692","article-title":"Prognostic factors in patients with carcinoma in situ treated with intravesical bacille Calmette-Guerin","volume":"38","author":"Andius","year":"2004","journal-title":"Scand J Urol Nephrol"},{"issue":"3","key":"10.1016\/j.urolonc.2021.05.006_bib0015","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/jjco\/hyq228","article-title":"The clinical impact of the classification of carcinoma in situ on tumor recurrence and their clinical course in patients with bladder tumor","volume":"41","author":"Hayakawa","year":"2011","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2021.05.006_bib0016","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000049765","article-title":"Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861","volume":"40","author":"Jakse","year":"2001","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2021.05.006_bib0017","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1442-2042.2008.02012.x","article-title":"Clinical outcomes of bacillus Calmette-Guerin instillation therapy for carcinoma in situ of urinary bladder","volume":"15","author":"Takenaka","year":"2008","journal-title":"Int J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2021.05.006_bib0018","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.juro.2010.03.134","article-title":"Clinical outcome of primary versus secondary bladder carcinoma in situ","volume":"184","author":"Chade","year":"2010","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2021.05.006_bib0019","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.ju.0000150425.09317.67","article-title":"Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer\u2013Genito-Urinary Group Phase III Trial (30906)","volume":"173","author":"de Reijke","year":"2005","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.05.006_bib0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.urolonc.2021.05.006_bib0021","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2021.05.006_bib0022","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2021.05.006_bib0023","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00428-018-2354-9","article-title":"Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications","volume":"472","author":"Barth","year":"2018","journal-title":"Virchows Arch"},{"issue":"1","key":"10.1016\/j.urolonc.2021.05.006_bib0024","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.eururo.2018.09.028","article-title":"Prognostic implication of the United States Food and Drug Administration-defined BCG-unresponsive disease","volume":"75","author":"Li","year":"2019","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921002118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921002118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:23:03Z","timestamp":1761042183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143921002118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1078143921002118"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.05.006","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of clinical and pathological subtypes of carcinoma in situ (CIS) of the bladder: Lessons learned from long-term follow-up of a series of CIS patients treated with BCG","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}